GBA Group enters US market to support growing demand from international clients
GBA Group, a leading European life science service provider, has entered the U.S. market with a site in Westborough, Massachusetts to support clinical trials. Located in the greater Boston area, a pharmaceutical and biotech hub, the laboratory and logistics site will be fully operational in October this year and will offer a broad range of services in the areas of central lab and clinical trial supply.
The foundation of the first site in the United States is a key element in GBA Group’s growth strategy in the pharmaceutical sector. With the expansion of pharmaceutical services in the U.S. market, the growing demand from international clients for project support in global clinical trials can be better served.
Steffen Walter, CEO, GBA Group, commented: “The establishment of our first site in the USA is a decisive step for GBA Group in the context of our global growth strategy. The expansion of our pharmaceutical services as a first step in the USA is to be followed by further ones also in other business areas of the GBA Group.”
Dr Sabine Gorynia, EVP Pharma & Medical Devices, GBA Group, said: “With the presence of our pharma services in the U.S. market, we are responding to the growing demand of our international customers and optimizing our high-quality services with regard to geography and processes. Our focus is on customer proximity, short lead times and smooth project execution.”
